Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Toll-like receptors (TLRs) 2, 3, 4, 7, and 9 are a subset of pattern recognition receptors (PRRs) that are essential components of the innate immune system, primarily expressed on antigen-presenting cells (APCs) such as dendritic cells and macrophages. These receptors detect specific pathogen-associated molecular patterns (PAMPs), including bacterial lipopolysaccharides (TLR4), lipoproteins (TLR2), double-stranded RNA (TLR3), single-stranded RNA (TLR7), and unmethylated CpG DNA (TLR9) (Source: UniProt). Upon activation, they initiate signaling cascades through adapter proteins like MyD88 or TRIF, resulting in the maturation of dendritic cells and the production of pro-inflammatory cytokines and interferons (Source: PubMed: 21115918). This activation is a critical bridge between innate and adaptive immunity, facilitating the priming of T-cell and B-cell responses. In clinical practice, these receptors are targeted by agonists to serve as vaccine adjuvants or to stimulate anti-tumor immunity in oncology (Source: NIH). However, dysregulated TLR signaling is also implicated in chronic inflammatory and autoimmune diseases, making them targets for both agonistic and antagonistic therapeutic strategies (Source: PubMed: 16751770). This target entry is technically a composite of five distinct receptors, each with unique structural and functional profiles.
Agonists bind to the leucine-rich repeat (LRR) domains of the receptors, inducing conformational changes that promote dimerization and recruitment of cytosolic adapter proteins MyD88 or TRIF. This initiates signaling cascades that activate NF-κB and IRF transcription factors, leading to the production of pro-inflammatory cytokines and Type I interferons (Source: PubMed: 16751770, UniProt).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Toll-like receptors 2, 3, 4, 7, and 9 (TLR2/3/4/7/9).